<DOC>
	<DOC>NCT02827032</DOC>
	<brief_summary>To perform post-market surveillance and evaluate the performance of the MobiusHD System in subjects with primary resistant hypertension.</brief_summary>
	<brief_title>Controlling and Lowering Blood Pressure With the MobiusHD™</brief_title>
	<detailed_description>The CALM-DIEM Trial is an open-label, prospective, multicenter study for patients who have been selected for treatment with the MobiusHD.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Mean 24hour systolic ABPM is ≥130 mmHg following at least 30 days on a stable antihypertensive medication regimen (no changes in medication or dose), and no more than 28 days prior to implantation. Known or clinically suspected baroreflex failure or autonomic neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypertension</keyword>
</DOC>